BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One 2016;11:e0149803. [PMID: 26910238 DOI: 10.1371/journal.pone.0149803] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 The Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019;18:797-807. [DOI: 10.1038/s41573-019-0034-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 25.3] [Reference Citation Analysis]
2 Ziv E, Durack JC, Solomon SB. The Importance of Biopsy in the Era of Molecular Medicine. Cancer J 2016;22:418-22. [PMID: 27870685 DOI: 10.1097/PPO.0000000000000228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
3 Ballarini NM, Rosenkranz GK, Jaki T, König F, Posch M. Subgroup identification in clinical trials via the predicted individual treatment effect. PLoS One 2018;13:e0205971. [PMID: 30335831 DOI: 10.1371/journal.pone.0205971] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
4 Johnson D, Hughes D, Pirmohamed M, Jorgensen A. Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. J Pers Med 2019;9:E42. [PMID: 31480618 DOI: 10.3390/jpm9030042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Vougas K, Sakellaropoulos T, Kotsinas A, Foukas GP, Ntargaras A, Koinis F, Polyzos A, Myrianthopoulos V, Zhou H, Narang S, Georgoulias V, Alexopoulos L, Aifantis I, Townsend PA, Sfikakis P, Fitzgerald R, Thanos D, Bartek J, Petty R, Tsirigos A, Gorgoulis VG. Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. Pharmacology & Therapeutics 2019;203:107395. [DOI: 10.1016/j.pharmthera.2019.107395] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
6 Lévy V. Of some innovations in clinical trial design in hematology and oncology. Therapie 2021:S0040-5957(21)00245-6. [PMID: 34922739 DOI: 10.1016/j.therap.2021.10.011] [Reference Citation Analysis]
7 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Pitzalis C, Choy EHS, Buch MH. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat Rev Rheumatol 2020;16:590-9. [PMID: 32887976 DOI: 10.1038/s41584-020-0491-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Burnett T, Mozgunov P, Pallmann P, Villar SS, Wheeler GM, Jaki T. Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Med 2020;18:352. [PMID: 33208155 DOI: 10.1186/s12916-020-01808-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Bhattacharyya A, Rai SN. Adaptive Signature Design- review of the biomarker guided adaptive phase -III controlled design. Contemp Clin Trials Commun 2019;15:100378. [PMID: 31289760 DOI: 10.1016/j.conctc.2019.100378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open 2018;8:e018320. [PMID: 29440155 DOI: 10.1136/bmjopen-2017-018320] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
12 Antoniou M, Kolamunnage-Dona R, Wason J, Bathia R, Billingham C, Bliss JM, Brown LC, Gillman A, Paul J, Jorgensen AL. Biomarker-guided trials: Challenges in practice. Contemp Clin Trials Commun 2019;16:100493. [PMID: 31788574 DOI: 10.1016/j.conctc.2019.100493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
13 Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S. Precision pharmacology for Alzheimer’s disease. Pharmacological Research 2018;130:331-65. [DOI: 10.1016/j.phrs.2018.02.014] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
14 Segarra I, Modamio P, Fernández C, Mariño EL. Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees. Front Pharmacol 2017;8:488. [PMID: 28785221 DOI: 10.3389/fphar.2017.00488] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
15 Trippa L, Alexander BM. Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. JCO 2017;35:JCO.2016.68.286. [DOI: 10.1200/jco.2016.68.2864] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
16 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Murphy S, Zweyer M, Mundegar RR, Swandulla D, Ohlendieck K. Proteomic serum biomarkers for neuromuscular diseases. Expert Review of Proteomics 2018;15:277-91. [DOI: 10.1080/14789450.2018.1429923] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
18 Yin G, Yang Z, Odani M, Fukimbara S. Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research 2021;13:248-58. [DOI: 10.1080/19466315.2020.1811146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H. Generating comparative evidence on new drugs and devices after approval. Lancet 2020;395:998-1010. [PMID: 32199487 DOI: 10.1016/S0140-6736(19)33177-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
20 Wilkinson J, Brison DR, Duffy JMN, Farquhar CM, Lensen S, Mastenbroek S, van Wely M, Vail A. Don’t abandon RCTs in IVF. We don’t even understand them. Human Reproduction 2019;34:2093-8. [DOI: 10.1093/humrep/dez199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
21 Hot A, Bossuyt PM, Gerke O, Wahl S, Vach W, Zapf A. Randomized test-treatment studies with an outlook on adaptive designs. BMC Med Res Methodol 2021;21:110. [PMID: 34074263 DOI: 10.1186/s12874-021-01293-y] [Reference Citation Analysis]
22 Lee KM, Wason J. Design of experiments for a confirmatory trial of precision medicine. J Stat Plan Inference 2019;199:179-87. [PMID: 31007363 DOI: 10.1016/j.jspi.2018.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Rocca A, Kholodenko BN. Can Systems Biology Advance Clinical Precision Oncology? Cancers (Basel) 2021;13:6312. [PMID: 34944932 DOI: 10.3390/cancers13246312] [Reference Citation Analysis]
24 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
25 Wilhelm-Benartzi CS, Mt-Isa S, Fiorentino F, Brown R, Ashby D. Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. Crit Rev Oncol Hematol 2017;110:49-61. [PMID: 28109405 DOI: 10.1016/j.critrevonc.2016.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Rejon-Parrilla JC, Jonsson P, Bouvy JC. Key enablers and barriers to implementing adaptive pathways in the European setting. Br J Clin Pharmacol 2019;85:1427-33. [PMID: 30849187 DOI: 10.1111/bcp.13916] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
28 Park JJ, Harari O, Dron L, Mills EJ, Thorlund K. Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials. Contemp Clin Trials Commun 2019;15:100396. [PMID: 31294127 DOI: 10.1016/j.conctc.2019.100396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Spiegelberg L, Houben R, Niemans R, de Ruysscher D, Yaromina A, Theys J, Guise CP, Smaill JB, Patterson AV, Lambin P, Dubois LJ. Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clin Transl Radiat Oncol 2019;15:62-9. [PMID: 30734002 DOI: 10.1016/j.ctro.2019.01.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
30 Bayes-Genis A, Voors AA, Zannad F, Januzzi JL, Mark Richards A, Díez J. Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. Eur Heart J 2018;39:2793-9. [PMID: 28204449 DOI: 10.1093/eurheartj/ehx027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
31 Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med 2017;7:E1. [PMID: 28125057 DOI: 10.3390/jpm7010001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
32 Slovin SF. The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies. Biomark Med 2017;11:1149-59. [PMID: 29186979 DOI: 10.2217/bmm-2017-0138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pardini M, Cutter G, Sormani MP. Clinical trial design for progressive MS trials. Mult Scler 2017;23:1642-8. [PMID: 29041873 DOI: 10.1177/1352458517729461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol 2016;13:591-602. [PMID: 27356875 DOI: 10.1038/nrcardio.2016.101] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 17.5] [Reference Citation Analysis]
35 Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol 2018;10:343-51. [PMID: 29606891 DOI: 10.2147/CLEP.S156708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
36 Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M. Optimized adaptive enrichment designs. Stat Methods Med Res 2019;28:2096-111. [PMID: 29254436 DOI: 10.1177/0962280217747312] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
37 Wang Z, Wang F, Wang C, Zhang J, Wang H, Shi L, Tang Z, Rosner GL. A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation. Statistics in Biopharmaceutical Research. [DOI: 10.1080/19466315.2021.1873843] [Reference Citation Analysis]
38 Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018;16:29. [PMID: 29490655 DOI: 10.1186/s12916-018-1017-7] [Cited by in Crossref: 162] [Cited by in F6Publishing: 143] [Article Influence: 40.5] [Reference Citation Analysis]
39 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
40 Lee KM, Brown LC, Jaki T, Stallard N, Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials 2021;22:203. [PMID: 33691748 DOI: 10.1186/s13063-021-05150-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Curtin F, Heritier S. The role of adaptive trial designs in drug development. Expert Review of Clinical Pharmacology 2017;10:727-36. [DOI: 10.1080/17512433.2017.1321985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
42 Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials 2021;100:106216. [PMID: 33246098 DOI: 10.1016/j.cct.2020.106216] [Reference Citation Analysis]
43 Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J Pers Med 2017;7:E19. [PMID: 29207572 DOI: 10.3390/jpm7040019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Vermaelen K, Waeytens A, Kholmanskikh O, Van den Bulcke M, Van Valckenborgh E. Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Semin Cancer Biol 2018;52:166-77. [PMID: 29170067 DOI: 10.1016/j.semcancer.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
45 Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, Sánchez-Gómez LM, Imaz-Iglesia I, Garcia P, Demotes J, Banzi R, Porcher R; PERMIT Group. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open 2022;12:e052926. [PMID: 35523482 DOI: 10.1136/bmjopen-2021-052926] [Reference Citation Analysis]
46 Ballarini NM, Burnett T, Jaki T, Jennison C, König F, Posch M. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Stat Med 2021;40:2939-56. [PMID: 33783020 DOI: 10.1002/sim.8949] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Kimani PK, Todd S, Renfro LA, Stallard N. Point estimation following two-stage adaptive threshold enrichment clinical trials. Stat Med 2018;37:3179-96. [PMID: 29855066 DOI: 10.1002/sim.7831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]